MESO Research and Charts

MESO - Mesoblast Ltd ADR (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 17.99	Change ⇑ +1.21 (+7.21%)	Volume 337,882
	Open 17.51	High 18.16	Low 17.51

8EMA (Daily) 17.17	40EMA (Daily) 17.73	50EMA (Daily) 17.68	STO (Daily) 24.813	MACD Hist (Daily) -0.005
8EMA (Weekly) 17.713	40EMA (Weekly) 16.01	50EMA (Weekly) 15.40	STO (Weekly) 44.232	MACD Hist (Weekly) -0.324


Company Profile
Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.